🟢 GlaxoSmithKline is trading 4.07% up today after ARTEMIS-008 data showed 54% lower death risk

GlaxoSmithKline is trading 4.07% up at $50.09 after positive Phase III ARTEMIS-008 data showed Ris-Rez reduced death risk by 54% versus topotecan in relapsed small-cell lung cancer.

• Median overall survival was 18.5 months with Ris-Rez versus 10.3 months with chemotherapy.
• Reuters reported statistically significant overall-survival improvement, supporting expectations for a potentially important oncology asset.